CYP26A1

Across TCGA pan-cancer cohorts, CYP26A1 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of CYP26A1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where CYP26A1 RNA is repressed in tumor relative to normal tissue. In most cancer types CYP26A1 is over-expressed in tumor, although a few such as LIHC and CHOL show the opposite, repressed pattern.

LIHC, COAD, and THCA are the cancer types where CYP26A1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP26A1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	−2.664	<.001	9	view →
COAD	All	All	+0.343	<.001	8	view →
THCA	All	All	+0.267	<.001	8	view →
LUAD	All	All	+0.531	<.001	7	view →
HNSC	Male	III,IV	+1.542	.016	6	view →
UCEC	All	All	+0.901	<.001	6	view →
LUSC	Male	All	+2.184	<.001	5	view →
STAD	All	All	+0.198	.002	5	view →
CHOL	Male	All	−3.268	<.001	4	view →
KICH	All	All	+0.387	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

CYP26A1–LIHC

Open the LIHC breakdown →